Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

David Liu, MD, MPH, MS


Medical Oncology

Make an Appointment

Physician

  • Physician
  • Assistant Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Immuno-oncology
  • Melanoma
  • Predictive Biomarkers

Diseases Treated

Contact Information

  • Office Phone Number617-632-5055

Board Certification:

  • Internal Medicine , 2015
  • Medical Oncology, 2019

Fellowship:

  • DFCI and Harvard Cancer Care, Hematology/Oncology

Residency:

  • Johns Hopkins Hospital, Internal Medicine

Medical School:

  • Johns Hopkins University School of Medicine

Recent Awards:

  • Damon-Runyon Physician-Scientist Training Grantee
  • ASCO Young Investigator Award
  • Society for Immunotherapy of Cancers-BMS Immunotherapy Translational Fellowship
  • AACR NextGen Stars

Research

Developing Computational Approaches to Dissecting Predictors of Therapeutic Response and Resistance



The Liu lab operates at the intersection of clinical oncology, molecular biology, and computational biology, developing computational approaches to dissect therapeutic resistance and susceptibility to chemo-, targeted-, and immuno-therapies in patient tumors. Two broad areas of inquiry exist in the lab:





  1. Development of parsimonious predictive models utilizing statistical and machine learning approaches and integrating clinical and molecular data to guide clinical management.


  2. Mapping of clinical tumor heterogeneity and evolution of resistance and metastasis, using longitudinally collected tumor samples from patients over time, treatments, development of resistance, and from different metastatic sites to develop insight into drivers of resistance and metastasis.


Integrated molecular drivers coordinate biological and clinical states in melanoma. Nat Genet. 2020 12; 52(12):1373-1383.
View in: PubMed

Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer. Clin Cancer Res. 2021 Apr 01; 27(7):2011-2022.
View in: PubMed

Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy. J Clin Invest. 2020 08 03; 130(8):4266-4281.
View in: PubMed

Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade. Cancer Discov. 2020 09; 10(9):1296-1311.
View in: PubMed

ATM Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer. Cancer Res. 2020 06 01; 80(11):2094-2100.
View in: PubMed

Identification of cancer driver genes based on nucleotide context. Nat Genet. 2020 02; 52(2):208-218.
View in: PubMed

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat Med. 2019 12; 25(12):1916-1927.
View in: PubMed

CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer. Cell Rep. 2019 11 19; 29(8):2355-2370.e6.
View in: PubMed

Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2019; 3.
View in: PubMed

Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer. Clin Cancer Res. 2019 09 15; 25(18):5561-5571.
View in: PubMed

Intrinsic Resistance to Immune Checkpoint Blockade in a Mismatch Repair-Deficient Colorectal Cancer. Cancer Immunol Res. 2019 08; 7(8):1230-1236.
View in: PubMed

Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. J Clin Oncol. 2019 06 01; 37(16):1403-1411.
View in: PubMed

Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group. Am J Hematol. 2019 05; 94(5):E146-E149.
View in: PubMed

Mechanisms of Resistance to Immune Checkpoint Blockade. Am J Clin Dermatol. 2019 Feb; 20(1):41-54.
View in: PubMed

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell. 2018 11 01; 175(4):984-997.e24.
View in: PubMed

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. J Clin Invest. 2018 10 01; 128(10):4441-4453.
View in: PubMed

Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Genet. 2018 09; 50(9):1271-1281.
View in: PubMed

ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer. Clin Cancer Res. 2019 02 01; 25(3):977-988.
View in: PubMed

The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2018 05; 50(5):645-651.
View in: PubMed

Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAFV600E Colorectal Cancer. Cancer Discov. 2018 04; 8(4):417-427.
View in: PubMed

Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. Nat Commun. 2017 12 19; 8(1):2193.
View in: PubMed

Toward Molecularly Driven Precision Medicine in Lung Adenocarcinoma. Cancer Discov. 2017 06; 7(6):555-557.
View in: PubMed

Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016 Aug 01; 2(8):1094-6.
View in: PubMed

The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. Genome Med. 2016 07 26; 8(1):79.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Ave
Boston, MA 02215
Get Directions

Ratings

Top